EI

Emerging infectious diseases

Emerging Infectious Diseases (ISSN: 1080-6059) is a U.S. government public health journal that publishes articles across multiple sections including research, dispatches, and letters, and provides access to its contents through PubMed Central.

Looking to publish in Emerging infectious diseases? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Immunology, Infectious Diseases
Impact Factor 6.6
Quartile Q1
Open Access Type Open
ISSN 1080-6040
eISSN 1080-6059
Invitation Only No
Cost Range Publishing in EID is free—no submission fees, page charges, costs for corrections, or other fees.

Submission Instructions

Emerging infectious diseases accepts the following article types. Click on an article type to view submission instructions.

Original Article

Cover Letter A cover letter is required and must indicate the proposed manuscript type and verify that all authors have seen and approved the final manuscript.
Abstract An abstract is required and must not exceed 150 words.
Manuscript Original Article text must not exceed 3,500 words and must use subheadings in the body of text.
References Original Articles must not exceed 50 references; citations are numbered in order of appearance and shown as italicized numbers in parentheses, and reference lists include the first 6 authors followed by “et al.”
Figures & Tables No maximum number of figures or tables is specified, but tables must be placed at the end of the manuscript and figures must be submitted as separate files (not embedded) with legends placed after the tables.
Reformat to Emerging infectious diseases using Livewrite Premium

Historical Review

Cover Letter A cover letter is required and must state the proposed manuscript type and verify that all authors have seen and approved the final manuscript.
Abstract An unstructured abstract is required and must not exceed 150 words.
Manuscript Body text must use freeform subheadings.
References Citations are numbered in order of appearance, with reference numbers in parentheses (not superscript) and italicized; list the first 6 authors then “et al.”
Figures & Tables Tables appear at the end of the manuscript (not embedded in the text) and figure legends are placed in the manuscript after the tables; figures are submitted as separate files (not embedded in Word).
Reformat to Emerging infectious diseases using Livewrite Premium

Perspective

Cover Letter Cover letter is required. It must indicate the proposed manuscript type and verify all authors have seen and approved the final manuscript.
Abstract Abstract is required and must not exceed 150 words. It must be unstructured.
Manuscript Text must not exceed 3,500 words. Body text must use freeform subheadings.
References References must not exceed 50. Citations must be numbered in order of appearance, using italicized numbers in parentheses; list first 6 authors then “et al.”
Figures & Tables No maximum number of figures or tables is specified. Tables must appear at the end of the manuscript, and figure legends must follow the tables.
Reformat to Emerging infectious diseases using Livewrite Premium

Synopsis

Cover Letter Cover letter is required. It must state the proposed manuscript type and verify all authors have seen and approved the final manuscript.
Abstract Abstract is required and must be unstructured. Maximum length is 150 words.
Manuscript Synopsis text must not exceed 3,500 words. Body text must use subheadings.
References Maximum 50 references. Citations must be numbered in order of appearance; reference list shows first 6 authors then “et al.”
Figures & Tables No maximum number of tables or figures is specified. Tables go at the end of the manuscript; figure legends appear after the tables, and figures are submitted as separate files.
Reformat to Emerging infectious diseases using Livewrite Premium

Research Letter

Cover Letter A cover letter is required and must state the proposed manuscript type and verify that all authors have seen and approved the final manuscript.
Abstract An unstructured abstract is required and must not exceed 50 words.
Manuscript Research Letter text must not exceed 800 words.
References Maximum 10 references; cite in order of appearance using numbered citations in parentheses (not superscript), and list the first 6 authors followed by “et al.”
Figures & Tables Figures and tables combined must not exceed 2 total; tables appear at the end of the manuscript and figure legends appear after the tables, with figures submitted as separate files (not embedded).
Reformat to Emerging infectious diseases using Livewrite Premium

Policy Review

Cover Letter A cover letter is required and must state the proposed manuscript type and verify that all authors have seen and approved the final manuscript.
Abstract An unstructured abstract is required and must not exceed 150 words.
Manuscript Policy Review text must not exceed 3,500 words and must use freeform subheadings in the body of the text.
References Maximum 50 references; citations are numbered in order of appearance with reference numbers in italicized parentheses, and the reference list includes the first 6 authors then “et al.”
Figures & Tables No maximum number of tables and figures is specified; tables are placed at the end of the manuscript (not embedded in text) and figures are submitted as separate files with figure legends placed after the tables.
Reformat to Emerging infectious diseases using Livewrite Premium

Recent Publications

Serologic Evidence of Hantavirus Exposure in Humans, Italy, 2004–2018

Giulia Faolotto, Anishia Wasberg, Rommel Iheozor-Ejiofor, Essi M. Korhonen, Rosalba Minisini, Tarja Sironen, Ruut Joensuu, Jiaxin Ling, Åke Lundkvist, Olli Vapalahti, Eili Huhtamo, Paolo Ravanini

10.3201/eid3209.261840
View Publication

Serologic Evidence of Hantavirus Exposure in Humans, Italy, 2004–2018

Giulia Faolotto, Anishia Wasberg, Rommel Iheozor-Ejiofor, Essi M. Korhonen, Rosalba Minisini, Tarja Sironen, Ruut Joensuu, Jiaxin Ling, Åke Lundkvist, Olli Vapalahti, Eili Huhtamo, Paolo Ravanini

10.3201/eid3209.260840
View Publication

Respiratory Syncytial Virus Suppression through Public Health and Social Measures, Hong Kong, China, 2020–2023

Yanfang Xu, Weijia Xiong, Xiaotong Huang, Benjamin J. Cowling, Tim K. Tsang

10.3201/eid3208.251887
View Publication

Outbreak of Hepatitis A Linked to Frozen Blueberries, the Netherlands, 2024–2025

Ingrid H.M. Friesema, Ingeborg L.A. Boxman, Ife A. Slegers–Fitz-James, Heather E. van Brug, Jessica C.J. Elzakkers, Gregorius J. Sips, Ellen P.A. Verspui-van der Eijk, Dana L.L. Adriaansens, Florien Dusseldorp, Sabiena G. Feenstra, Harry Vennema, Eelco Franz

10.3201/eid3208.251406
View Publication

Rapid Expansion of Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Genotype D1.1 Virus across Flyway Regions, North America, Fall 2024

Matthew Scotch, Temitope O.C. Faleye, Angelica Urquidez-Negrete, Arvind Varsani, Ann Fan, Anne Justice-Allen

10.3201/eid3208.260205
View Publication

Frequently asked questions

How long does it take to publish?

Comment letters are more likely to be published if submitted within 4 weeks of the original article’s publication.

Reformat to Emerging infectious diseases using Livewrite Premium

Is a cover letter required?

A cover letter is required with submission and must indicate the proposed manuscript type and verify that all authors have seen and approved the final manuscript.

Reformat to Emerging infectious diseases using Livewrite Premium

What are the publication costs?

Publishing in EID is free—no submission fees, page charges, costs for corrections, or other fees.

Reformat to Emerging infectious diseases using Livewrite Premium

Research Topics

Viral Infections and Vectors Mosquito-borne diseases and control Viral gastroenteritis research and epidemiology Influenza Virus Research Studies Vector-borne infectious diseases Viral Infections and Outbreaks Research Animal Disease Management and Epidemiology COVID-19 epidemiological studies Respiratory viral infections research Mycobacterium research and diagnosis SARS-CoV-2 and COVID-19 Research Vector-Borne Animal Diseases Tuberculosis Research and Epidemiology Zoonotic diseases and public health Malaria Research and Control Salmonella and Campylobacter epidemiology Antibiotic Resistance in Bacteria Pneumonia and Respiratory Infections Bacillus and Francisella bacterial research Vibrio bacteria research studies Animal Virus Infections Studies Virology and Viral Diseases Streptococcal Infections and Treatments Yersinia bacterium, plague, ectoparasites research Antimicrobial Resistance in Staphylococcus

Related Journals

FI
Frontiers in Cellular and Infection Microbiology Frontiers Media
DM
Diagnostic Microbiology and Infectious Disease Elsevier BV
HV
Human Vaccines & Immunotherapeutics Taylor & Francis
JO
Journal of Chemotherapy Taylor & Francis
MO
Mediators of Inflammation Hindawi Publishing Corporation
TL
The Lancet Infectious Diseases Elsevier BV